Advances in computing technology continue to drive the development of small, hand-held ultrasound scanners. The latest firm to join the race is Terason, which has developed a full-function ultrasound scanner that fits completely inside a probe.Introduced
Advances in computing technology continue to drive the development of small, hand-held ultrasound scanners. The latest firm to join the race is Terason, which has developed a full-function ultrasound scanner that fits completely inside a probe.
Introduced at the 1999 RSNA meeting, Terason 2000 weighs just 8 to 10 ounces, and includes front-end image pulser/receivers, a 128-channel digital beamformer, and a scan converter all in one unit. The system supports B-mode, color, power, and spectral Doppler scanning. Linear, curved linear, and phased array formats are available.
The ultrasound probe then connects via a FireWire to any PC that runs on Microsofts Windows NT 4.0 or higher, making PCs capable of becoming ultrasound systems simply by clicking on an icon, said Kerr Spencer, senior vice president of marketing and sales for the Burlington, MA-based firm.
We wanted to leverage the revolutions in the PC and communications industries, and make ultrasound a plug-and-play system like a digital video camera, Spencer said.
A local information management system is available, as is DICOM 3.0 support. Users can also perform image measurements, report generation, printing, and text annotation. In future developments, Terason will add M-mode imaging, tissue harmonic imaging, voice recognition software, and telemedicine capabilities.
To accomplish the task of combining all ultrasound functions into such a small space, Terason employs advanced application-specific integrated circuits (ASICs) and low-power technologies, he said. The firms proprietary charge domain processing (CDP) technology combines high-speed, low power sampled, data charge domain components with CMOS digital control and memory circuits. The result is a new type of microelectronics that provides fast computation capability, low power consumption, and easy integration into PC operating systems, according to the firm.
Clinical testing is under way at several sites, and Terason is in the process of setting up a clinical advisory board. The company is still evaluating its distribution model, but will likely market Terason 2000 through a mix of direct and dealer sales, both in the U.S. and in Europe and Asia, according to Spencer. Terason is also interested in setting up an e-commerce capability for system sales.
The system will range in price between $25,000 and $50,000. First customer shipments are set to begin in June. The vendor received Food and Drug Administration 510(k) clearance for Terason 2000 in November 1999.
While Terason believes that Terason 2000 is suitable for such traditional ultrasound applications as radiology, cardiology, ob/gyn, and urology, the company also hopes the system will be implemented in environments such as emergency rooms, intensive care units, and surgical suites. Terasons new clinical advisory board will help develop educational programs for these sectors as well as identify other target markets for the system.
We believe this is also a new product for new users, Spencer said.
Terason is a division of Teratech, a spin-off of the Massachusetts Institute of Technologys Lincoln Laboratory that was formed in 1994. Other divisions of Teratech are active in developing sonar applications and digital signal processing for the military. Teratech has received funding from the U.S. Department of Defenses Advanced Research Project Agency (DARPA).
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Contrast-Enhanced Mammography Study Reveals 24 Percent Lower Sensitivity with Moderate/Marked BPE
April 30th 2025In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.